




- 1 -

LISTING OF CLAIMS






CLAIMS 1-15 (canceled)

16- (currently amended) A compound of formula (I):



wherein:

- R¹ represents hydrogen, halogen, alkyl, polyhaloalkyl, cyano, nitro, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl,
- R² represents hydrogen, alkyl, optionally substituted aryl, optionally substituted heteroaryl, or R²⁰-C(X)- wherein :
 - R²⁰ represents alkyl, alkoxy, amino, alkylamino, dialkylamino, optionally substituted aryl or optionally substituted heteroaryl,
 - X represents oxygen, sulphur, or NR²¹ wherein R²¹ represents hydrogen or alkyl,
- R³ represents hydrogen or alkyl,
- n represents an integer from 1 to 6 inclusive,

- the representation R¹- means: R¹-, R¹-, R¹- or R¹-,

its enantiomers, diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base,

~~it being understood that:~~

- the term "alkyl" denotes linear or branched hydrocarbon chain having from 1 to 6 carbon

atoms,

- the term "alkoxy" denotes an alkyl-oxy in which the alkyl chain, which is linear or branched, has from 1 to 6 carbon atoms,

- the term "aryl" denotes phenyl or biphenyl,

5 - the term "polyhaloalkyl" denotes a linear or branched carbon chain having from 1 to 3 carbon atoms and from 1 to 7 halogen atoms,

- the term "heteroaryl" denotes a group having from 5 to 11 ring members which is monocyclic or bicyclic, in which at least one of the rings is aromatic, and which contains in the monocyclic ring system or in the bicyclic ring system 1, 2 or 3 hetero atoms
10 selected from nitrogen, oxygen and sulphur, and

- the expression "optionally substituted" associated with the expressions aryl and heteroaryl means that the groups in question ~~are~~ may be substituted by one or two identical or different substituents selected from halogen, alkyl, alkoxy, polyhaloalkyl, hydroxy, cyano, nitro, amino (optionally substituted by one or two alkyl groups) and -C(O)R_d
15 wherein R_d represents a group selected from hydroxy, alkoxy and amino, ~~it being understood that~~ and wherein the heteroaryl may also be substituted by an oxo moiety on the non-aromatic moiety of the heteroaryl.

17- (previously presented) A compound of Claim 16, wherein the representation



20 **18-** (previously presented) A compound of Claim 16, wherein R¹ represents hydrogen.

19- (previously presented) A compound of Claim 16, wherein R² represents hydrogen.



20- (previously presented) A compound of Claim 16, wherein R² represents a group R²⁰-C(O)-.

21- (previously presented) A compound of Claim 16, wherein R³ represents hydrogen.

25 **22-** (previously presented) A compound of Claim 16, wherein R²⁰ represents alkoxy.

23- (previously presented) A compound of Claim 16, wherein n represents an integer from 4 to 6 inclusive.

24- (previously presented) A compound of Claim 16, wherein

 represents , R¹ represents hydrogen, R² represents hydrogen or a group
5 R²⁰-C(O)-, wherein R²⁰ represents alkoxy, and n is 4 or 5.

25- (previously presented) A compound of Claim 16, which is 3-cycloheptyl-3*H*-imidazo[4,5-*b*]pyridine-2-amine.

26- (previously presented) A compound of Claim 16, which is 3-cyclooctyl-3*H*-imidazo[4,5-*b*]pyridine-2-amine.

10 **27-** (previously presented) A pharmaceutical composition useful as an AMPK activator, comprising as active principle and effective amount of a compound as claimed in Claim 16, together with one or more inert, non-toxic, pharmaceutically acceptable excipients or vehicles.

28- (currently amended) A method for treating a living animal body, ~~including a human,~~
15 afflicted with a condition selected from non-insulin-dependent, type II diabetes, obesity,
type I diabetes, hyperlipidaemia, hypercholesterolaemia and their cardiovascular
complications, comprising the step of administering to the living animal body, ~~including a~~
~~human,~~ an amount of a compound of Claim 16, which is effective for alleviation of the
condition.

20 **29-** (currently amended) A method for treating a living animal body, ~~including a human,~~
afflicted with a condition selected from type I and II diabetes and their cardiovascular
complications, comprising the step of administering to the living animal body, ~~including a~~
~~human,~~ an amount of a compound of Claim 16, which is effective for alleviation of the
condition.

25 **30-** (currently amended) A method for treating a living animal body, ~~including a human,~~

afflicted with a condition selected from type I and II diabetes, comprising the step of administering to the living animal body, ~~including a human~~, an amount of a compound of Claim 16, which is effective for alleviation of the condition.

5 **31**- (new) A method for treating a human afflicted with a condition selected from non-insulin-dependent, type II diabetes, obesity, type I diabetes, hyperlipidaemia, hypercholesterolaemia and their cardiovascular complications, comprising the step of administering to the human an amount of a compound of Claim 16, which is effective for alleviation of the condition.

10

32- (new) A method for treating a human afflicted with a condition selected from type I and II diabetes and their cardiovascular complications, comprising the step of administering to the human an amount of a compound of Claim 16, which is effective for alleviation of the condition.

15

33- (new) A method for treating a human afflicted with a condition selected from type I and II diabetes, comprising the step of administering to the human an amount of a compound of Claim 16, which is effective for alleviation of the condition.